Last updated on January 2019

Study of CLR 131 in Relapsed or Refractory Select B-Cell Malignancies


Brief description of study

This study evaluates CLR 131 in patients with select B-cell malignancies (multiple myeloma( MM), indolent chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), lymphoplasmacytic lymphoma (LPL), marginal zone lymphoma (MZL), mantle cell lymphoma (MCL), and diffuse large B-cell lymphoma (DLBCL) who have been previously treated with standard therapy for their underlying malignancy.

Detailed Study Description

B-cell malignancies represent a diverse collection of diseases and, taken together, make up the majority of hematologic malignancies. B-cell lymphomas represent the largest percentage of these neoplasms, and the relapsed and/or refractory B-cell lymphomas have proven very difficult to treat. Success rate, defined as complete or partial response, is as low as 2% to 4% in many of these diseases, and they remain an area of a significant unmet medical need.

CLR 131 is a radioiodinated therapeutic that exploits the selective uptake and retention of phospholipid ethers (PLEs) by malignant cells. Cellectar Biosciences' novel cancer-targeted small-molecule compound (CLR1404) is radiolabeled with the isotope iodine-131 (I-131). Radioiodinated CLR1404 has been evaluated in over 60 xenograft and spontaneous (transgenic) tumor models. In all but two cases of hepatocellular carcinoma, CLR1404 demonstrated selective cancer cell uptake and retention. In various rodent tumor models, CLR 131 has also demonstrated tumor growth delay and prolongation of survival.

Based on the critical unmet medical need for effective agents with novel mechanisms of action in B-cell malignancies, the radiosensitivity of these cancers, and initial preclinical and clinical experience with radioiodinated CLR1404, Cellectar Biosciences has chosen to assess CLR 131 in a phase 2 trial.

Clinical Study Identifier: NCT02952508

Find a site near you

Start Over

Cellectar Biosciences site

Jacksonville, FL United States
  Connect »

Cellectar Biosciences site

Maywood, IL United States
  Connect »

Cellectar Biosciences site

New Orleans, LA United States
  Connect »

Cellectar Biosciences site

Rochester, NY United States
  Connect »

Cellectar Biosciences

Greenville, SC United States
  Connect »

Cellectar Biosciences site

Seattle, WA United States
  Connect »

Cellectar Biosciences site

Redlands, CA United States
  Connect »

Cellectar Biosciences site

Warrenville, IL United States
  Connect »

Cellectar Biosciences site

Westwood, KS United States
  Connect »

Cellectar Biosciences site

Madison, WI United States
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.